Sign in5 stories
The company filed an Orphan Drug Designation request on September 30, 2026 for intranasal foralumab in multiple system atrophy, a rare disease with no approved disease-modifying treatments.
SEC filing
The company said database lock is expected within the week, with topline 12-week data from the intranasal foralumab study due in October 2026.
SEC filing
The company shared trial design details for its Phase 2a ALS study at ALS Nexus 2026 on August 24, though enrollment specifics are still pending.
SEC filing
Tiziana Life Sciences said CEO Ivor Elrifi bought company stock on Nasdaq on August 4 and August 6, 2026, each time at $1.00 per share.
SEC filing (2)